NESS ZIONA, Israel and SOPHIA-ANTIPOLIS, France, April 29 Foamix Ltd, a global leader in the development of dermatological foammedications and Galderma, a worldwide specialty pharmaceutical companyfocused on dermatology, today announced that they have signed an agreement todevelop an innovative medicated foam jointly. This new treatment contains anovel drug for the therapy of certain skin diseases.
Under this agreement, Foamix will develop the foam formulation of theproduct and Galderma will subsequently conduct all other activities(clinical, non-clinical, etc). Foamix will receive staged payments onsuccessful completion of the technical milestones of the project.
Headquartered in Ness Ziona, Israel, Foamix Ltd. is a leading developerof topical foams for dermatology and gynecology. Foamix's state-of-the-artfoams provide controlled delivery of a variety of active ingredients. Foamixis a privately held company, whose business model is based on partnering withleading pharma companies to develop products utilizing its proprietary foamtechnologies. Foamix is currently collaborating with 10 pharmaceuticalcompanies on 11 projects in the development of proprietary dermatological andgynecologic foam drugs, and has its own in-house pipeline of dermatologicaland gynecological drugs in foam presentation. Foamix holds 4 US patents andhas 62 US patents pending, with further filings worldwide.
For additional information, please visit http://www.foamix.co.il.
Galderma, created in 1981 as a joint venture between Nestle and L'Oreal,is a fully integrated specialty pharmaceutical company dedicated exclusivelyto the field of dermatology. The Company is present in 65 countries, withover 1,000 sales representatives and is committed to improving the health ofskin with an extensive line of products to treat a range of dermatologicalconditions including: acne, rosacea, fungal nail infections, psoriasis &steroid-responsive dermatoses, pigmentary disorders, skin cancers and medicalsolutions for skin senescence. With a new research and development center inSophia Antipolis, France, Galderma has one of the largest R&D facilitiesdevoted exclusively to dermatology. Leading dermatology brands includeDifferin(R), Rozex(R)/Metro(R), Clobex(R), Tri-Luma(R), Loceryl(R) andCetaphil(R). Recently launched products include Pliaglis(TM), a topicalanaesthetic for dermatologic procedures in the United-States, Epiduo(R), aninnovative combination product for the acne treatment in Europe andArgentina, and Dysport(R), a botulinum toxin type A product for use inaesthetic medicine and dermatological indications in Brazil and Argentina.The company's website is http://www.galderma.com. For further information: Foamix Galderma Sigal Maymon Leila Zarif Business Development Associate Head of Licensing Tel: +972-8-9316233 Tel: +33(0)4-92-95-29-30 e-mail: email@example.com e-mail: firstname.lastname@example.org
SOURCE Foamix Ltd